; (II) clause (iv) or (v) of paragraph (5)(B) of this subsection; (III) clause (iii) or (iv) of paragraph (5)(F) of this subsection; (IV) section 505A; (V) section 505E; or (VI) section 527(a). . (c) Removal of invalid patents (1) In general Section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355(j)(7) ) is amended by adding at the end the following: (D) (i) The holder of an application approved under subsection (c) for a drug on the list shall promptly notify the Secretary in writing if either of the following occurs: (I) The Patent Trial and Appeals Board issues a decision that a patent for such drug is invalid. (II) A court issues a decision from which no appeal may be taken that a patent for such drug is invalid. (ii) The holder of an approved application shall include in any notification under clause (i) a copy of the decision described in subclause (I) or (II) of clause (i). (iii) The Secretary shall remove from the list any patent that is determined to be invalid in a decision described in subclause (I) or (II) of clause (i)— (I) promptly; but (II) not before the expiration of any 180-day exclusivity period under clause (iv) or (v) of paragraph (5)(B) that relies on a certification described in paragraph (2)(A)(vii)(IV) that such patent was invalid. . (2) Applicability Subparagraph (D) of section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355(j)(7) ), as added by paragraph (1), applies only with respect to a decision described in such subparagraph that is issued on or after the date of enactment of this Act. (d) Review and report Not later than one year after the date of enactment of this Act, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall— (1) review the types of patent information that should be included on the list under section 507(j)(7) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355(j)(7) )